TransMedics Group (NASDAQ:TMDX) Sets New 12-Month Low – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $55.00 and last traded at $56.73, with a volume of 2322802 shares trading hands. The stock had previously closed at $57.20.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of research analyst reports. TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Trading Up 0.9 %

The firm has a market cap of $2.10 billion, a PE ratio of 66.54 and a beta of 2.12. The company has a 50-day simple moving average of $69.56 and a 200 day simple moving average of $115.95. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the company posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Perigon Wealth Management LLC lifted its stake in shares of TransMedics Group by 212.4% in the fourth quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company’s stock worth $828,000 after buying an additional 9,707 shares in the last quarter. Sachetta LLC purchased a new position in TransMedics Group in the 4th quarter worth approximately $40,000. Cornerstone Wealth Management LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $231,000. Janney Montgomery Scott LLC acquired a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $239,000. Finally, HB Wealth Management LLC lifted its position in TransMedics Group by 49.2% during the fourth quarter. HB Wealth Management LLC now owns 8,149 shares of the company’s stock worth $508,000 after buying an additional 2,689 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.